Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome

Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome

OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the atypical neuroleptic risperidone (RIS) in the treatment of children and adults with moderate to severe Tourette Syndrome.

II. Evaluate further the safety of RIS in this population.

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Initially, all patients receive placebo capsules twice daily in a single blind fashion during the first 2 weeks of study.

Then, patients are randomized to receive either risperidone (RIS) or placebo for 8 weeks. The dose of RIS is increased weekly over the first 4 weeks of treatment, as tolerated.

Patients continue RIS for 4 additional weeks at the dose prescribed during week 4.

All patients receive diagnostic evaluations at the beginning and end of the 2 week initial single blind phase, and at the end of weeks 2, 4, 6, and 8 of the active treatment phase.

Phase 2
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
  • Tourette Syndrome
    * Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
    July 1997
    September 2000


    --Disease Characteristics--

    DSM-IV diagnosis of Tourette Syndrome (TS)

    Tic symptoms greater than 3 (moderate or worse) on the Global Clinical Impression Scale for TS

    --Prior/Concurrent Therapy--

    No concurrent use of other medications during study

    A minimum of 4 weeks since prior use of other medications and 8 weeks for neuroleptics or fluoxetine

    --Patient Characteristics--

    Hepatic: No hepatic disease

    Renal: No renal disease


    • No heart disease

    • No hypertension

      Pulmonary: No pulmonary disease


    • Not pregnant

    • IQ at least 70 required

    • No other movement disorder allowed, such as tardive dyskinesia

    • No major depression

    • No pervasive developmental disorder

    • No autism or psychotic disorder based on DSM-IV

    • No alcohol or substance abuse

    • No hypersensitivity to risperidone

    • All subjects must be in good health

    7 Years - 60 Years
    • , ,
    • , ,
    National Center for Research Resources (NCRR)
    • Yale University
    Study Chair: Bradley S. Peterson, Yale University
    Office of Rare Diseases (ORD)
    March 2001
    October 18, 1999
    June 23, 2005
    Required WHO trial registration data element.
    †† WHO trial registration data element that is required only if it exists.